Item 3. Legal Proceedings
Item 3. Legal Proceedings
We have no current legal proceedings.
Item 4. Mine Safety Disclosures
Not applicable.
Item 4.1 Information About Our Executive Officers
The following information sets forth the names,
ages, and positions of our executive officers as of March 10, 2023.
Name
Age
Positions and Offices Held
William J. Febbo
54
Chief Executive Officer
Stephen L. Silvestro
45
Chief Commercial Officer
Marion Odence-Ford
58
General Counsel and Chief Compliance Officer
Edward Stelmakh
57
Chief Financial Officer and Chief Operations Officer
Todd Inman
67
Chief Technology Officer
Doug Besch
41
Chief Product Officer
Set forth below is a brief description of the
background and business experience of each of our current executive officers.
14
William J. Febbo
Mr. Febbo joined the Company as Chief Executive
Officer and as a director in February 2016. Mr. Febbo founded Plexuus, LLC, a payment processing business for medical professionals in
September 2015 and remained its Chairman from September 2015 to December 2020. From April 2007 to September 2015, Mr. Febbo served as
Chief Operating Officer of Merriman Holdings, Inc., an investment banking firm, where he assisted with capital raises in the tech, biotech,
cleantech, consumer and resources industries. Mr. Febbo was a co-founder of, and from September 2013 to September 2015 served as Chief
Executive Officer of, Digital Capital Network, Inc., a transaction platform for institutional and accredited investors. Mr. Febbo was
a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC, a provider of market intelligence
and communications for the pharmaceutical, biomedical, and medical device industries. Since 2017, Mr. Febbo has been a faculty member
of the Massachusetts Institute of Technology’s linQ program, which is a collaborative initiative focused on increasing the potential
of innovative research to benefit society and the economy. Mr. Febbo currently serves as a director of Modular Medical (NASDAQ: MODD),
a development stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump , and as a director of Augmedix, Inc. (NASDAQ: AUGX), a provider of automated medical
documentation and data services. In addition, Mr. Febbo has been a board member of the United Nations Association of Greater Boston, a
resource for the citizens of Greater Boston on the broad agenda of critical global issues addressed by the UN and its agencies, since
2004.
On January 29, 2018, FINRA accepted a Letter of
Acceptance, Waiver and Consent (the “Consent”) submitted by William Febbo. Without admitting or denying the findings, Mr.
Febbo consented to the sanctions and to the entry of findings that he permitted Merriman Capital, Inc. to conduct a securities business
while below its net capital requirement. From August 2012 to October 2015, Mr. Febbo was the Financial and Operations Principal (FinOp)
for a registered broker-dealer, Merriman Capital, Inc. (“Merriman”). During certain months while Mr. Febbo was FinOp, FINRA
found that certain of Merriman’s net capital filings with FINRA were inaccurate because of the method by which Merriman calculated
net capital and that, when corrected, it was retroactively determined that Merriman had operated below its minimum net capital requirements.
Mr. Febbo, as FinOp, signed certain of these reports and was thus held responsible. Based on the Consent, in settlement, Mr. Febbo, who
was then no longer registered with any broker-dealer, accepted a fine of $5,000, a 10-business day suspension from acting as FinOp for
any FINRA member and required to requalify by examination for the Series 27 license before again acting in a FinOp capacity.
Stephen L. Silvestro
Mr. Silvestro joined the Company as Chief Commercial
Officer on April 29, 2019. Mr. Silvestro was with CCH® Tagetik, a Wolters Kluwer company that provides corporate performance management
software solutions for planning, consolidation and reporting, as its Vice President and General Manager from January 2018 until April
2019. From April 2017 to January 2018, Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief
Commercial Officer and, before that, from September 2007 to April 2017, he was with Decision Resources Group, a multi-national corporation
that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare
provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global
Sales.
Marion Odence-Ford
Ms. Odence-Ford joined the Company as General
Counsel & Chief Compliance Officer in February 2021. From April 2013 to June 2020, Ms. Odence-Ford was Vice President & Deputy
General Counsel at Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and
consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. From November
2004 to November 2012, Ms. Odence-Ford was Vice President & Associate General Counsel at CRA International, Inc. (dba Charles River
Associates) (NASDAQ: CRAI), a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations,
accounting firms, and governments around the world. From May 2004 to November 2004, Ms. Odence-Ford was a member of the GTC Law Group,
LLP, a law firm specializing in the business affairs of companies in the high tech and biotech industries. Prior to joining the GTC Law
Group, Ms. Odence-Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation (NYSE: BAC) from November
2002 to May 2004, and Akamai Technologies, Inc. (NASDAQ: AKAM) from October 1999 to November 2002. Ms. Odence-Ford began her legal career
in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate
matters.
15
Edward Stelmakh
Mr. Stelmakh joined the Company as Chief Financial
Officer and Chief Operating Officer on October 11, 2021. Prior to joining the Company, Mr. Stelmakh served as Senior Vice President, Chief
Financial Officer and Chief Operating Officer of Otsuka America Pharmaceuticals Inc. (“Otsuka”), a US division of a Japanese
global healthcare enterprise, since April 2020. Previously, he held various positions at Otsuka including Senior Vice President and Chief
Financial Officer (December 2017 – March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017).
From March 2010 to December 2015, Mr. Stelmakh worked at Covance, a division of LabCorp, Inc., as Vice President, Finance, Clinical Development
and Commercialization Services. Prior thereto, Mr. Stelmakh held a variety of positions of increasing responsibilities at Johnson &
Johnson, Sanofi-Aventis, Organon/Schering-Plough and Mylan.
Todd Inman
Mr. Inman joined the Company on January 1, 2019
as Vice President, Technology and became the Company’s Chief Technology Officer in November 2019. Prior to joining the Company,
from May 2017 to December 2018, Mr. Inman was the Founder and Chief Technology Officer of Meghadata, LLC, a master data management firm,
and from July 2016 to December 2017, Mr. Inman was the Founder and Managing Partner of Data Solutions Partners, a data intelligence solutions
company. From January 2011 through June 2016, Mr. Inman was Director of Data Solutions at Change HealthCare, a healthcare technology and
business solutions company, and from 2005 to 2011, Mr. Inman was the Director of Data Integration of Emdeon Business Services, LLC, an
information technology and services company. Prior to Emdeon, from 2001 to 2005, Mr. Inman was the Director of Clearinghouse Services
at WebMD Health Corp and, from 1996 to 2001, he was the Manager of Clearinghouse Operations at Professional Office Systems, a CareFirst
subsidiary, providing medical office electronic data interchange services.
Doug Besch
Dr. Besch joined the Company on May 24, 2021 as
SVP Product Strategy & Innovation and became the Company’s Chief Product Officer in October 2022. Prior to joining the Company, from
January 2018 to May 2021, Dr. Besch was the Vice President over Payor and Market Access Solutions for Clarivate (previously Decision Resources
Group (DRG)), a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical,
biotech, medical device, healthcare provider and payer, and managed care companies. Prior to Clarivate, from January 2012 to June 2017,
Dr. Besch was a co-founder and the Chief Product Officer for Rx Savings Solution, a company which helps members
and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge
support . Dr. Besch holds a PharmD and MBA from Creighton University and practiced as a pharmacist for the Walgreens Boots Alliance
corporation from 2007 through 2013.
16
PART II